TY  - JOUR
AU  - Carmona-Bayonas, A
AU  - Jiménez-Fonseca, P
AU  - Custodio, A
AU  - Sánchez Cánovas, M
AU  - Hernández, R
AU  - Pericay, C
AU  - Echavarria, I
AU  - Lacalle, A
AU  - Visa, L
AU  - Rodríguez Palomo, A
AU  - Mangas, M
AU  - Cano, J M
AU  - Buxo, E
AU  - Álvarez-Manceñido, F
AU  - García, T
AU  - Lorenzo, J E
AU  - Ferrer-Cardona, M
AU  - Viudez, A
AU  - Azkarate, A
AU  - Ramchandani, A
AU  - Arias, D
AU  - Longo, F
AU  - López, C
AU  - Sánchez Bayona, R
AU  - Limón, M L
AU  - Díaz-Serrano, A
AU  - Fernández Montes, A
AU  - Sala, P
AU  - Cerdá, P
AU  - Rivera, F
AU  - Gallego, J
AU  - AGAMENON study group
PY  - 2017
DO  - 10.1007/s10120-017-0718-5
UR  - http://hdl.handle.net/10668/11073
T2  - Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
AB  - Although anthracycline-based triplets are one of the most widely used schedules to treat advanced gastric cancer (AGC), the benefit of including epirubicin in these therapeutic combinations remains unknown. This study aims to evaluate both the...
LA  - en
KW  - Anthracyclines
KW  - Epirubicin
KW  - Gastric cancer
KW  - Stomach
KW  - Triplets:doublets
KW  - Adenocarcinoma
KW  - Adult
KW  - Aged
KW  - Anthracyclines
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Cisplatin
KW  - Female
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Proportional Hazards Models
KW  - Pyrimidines
KW  - Registries
KW  - Stomach Neoplasms
TI  - Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry.
TY  - research article
VL  - 21
ER  -